

Highlights of Emergency ACIP Meeting
Dec. 12, 2020
by Stan Grogg, DO
American Osteopathic Association's Liaison Member

ACIP Recommended:

The Pfizer-BioNTech COVID-19 vaccine is recommended for persons 16 years of age and older in the U.S. population under the FDA's Emergency Use Authorization.

Pfizer yesterday indicated the vaccine could be stored for 5 days in refrigerator
A CDC tool kit will be sent to healthcare providers. <https://www.cdc.gov/coronavirus/2019-ncov/communication/toolkits/index.html>.

Evidence to Recommendation Framework: Pfizer-BioNTech COVID-19 vaccine by Sara Oliver, MD
FDA EUA recommendation for Pfizer-BioNTech vaccine (2 doses, IM) was recommended for 16 years of age and older under an Emergency Use Authorization.

Epidemiology:

Cases of COVID Infections in the US = 15,474,800 Dec., 278.7 per 1000,000 per hospitalization with mortality of 291,522 as of Dec. 10, 2020. Fatality ratio range from 0.5% to 1.4%.

Pfizer-BioNTech COVID -19 Vaccine

Overall efficacy was 95%

For hospitalization due to COVID-19, 5 events occurred, all in the placebo group. Vaccine effectiveness against hospitalization was 100%

Deaths in vaccine group 2, 4 in placebo group

Overall acceptability of a COVID-19 was moderate (70% in November survey); lowest among Black respondents and greatest among higher socioeconomic status.

The vaccine will be free of charge to U.S. Population.

Because of Cold-chain storage issues, limited number and types of facilities can receive and use the vaccine (large health centers or central distribution sites rather than local community setting)

Emphasis need 2 doses

ACIP COVID-19 workgroup felt desirable consequences clearly outweigh undesirable consequences in most settings.

Clinical considerations: (2 dose series 3 weeks apart with 2nd dose within 4-day grace period considered valid.

Cannot interchange with other COVID-19 vaccine products.

Should not be given within 14 days of other vaccinations.

Should be offered to persons regardless of history or prior symptomatic or asymptomatic SARS-CoV-2 infection. Person with known current COVID-19 infection should be deferred until recovery from acute illness. Persons with a known COVID-19 should defer vaccination until quarantining period has ended.

Should be deferred for 90 days to persons who received passive antibody therapy for COVID-19.

Persons with underlying medical conditions may be vaccinated who have no contraindication to vaccination.

HIV and other immunocompromising conditions can be vaccinated.

Pregnant women: may receive vaccine if part of a group such as healthcare personnel who is recommended to receive and if a pregnant woman chooses after informed decision.

In general, Breastfeeding/lactating women is not a contraindication for vaccination.

Reactogenicity: before vaccination, providers should counsel vaccine recipients about expected local and systemic post-vaccination symptoms. Antipyretic or analgesic medication may be taken for treatment of post-vaccination symptoms.

Because of reports of anaphylactic reactions vaccinated outside of clinical trials, persons having severe allergic reaction to any vaccine or injectable therapy, patients should be observed for 15 minutes if bad allergies and if history of anaphylaxis for 30 minutes.

ACIP Voted to recommend the Pfizer-BioNTech COVID-19 Vaccine

The Pfizer-BioNTech COVID-19 vaccine is recommended for persons 16 years of age and older in the U.S. population under the FDA's Emergency Use Authorization.

Recommend the proposed amendment to the 2021 Adult and Child/Adolescent immunization Schedules